These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25824215)

  • 21. Rifapentine.
    Jarvis B; Lamb HM
    Drugs; 1998 Oct; 56(4):607-16; discussion 617. PubMed ID: 9806107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Rifabutin or Rifampin on Bedaquiline Safety, Tolerability, and Pharmacokinetics Assessed in a Randomized Clinical Trial with Healthy Adult Volunteers.
    Healan AM; Griffiss JM; Proskin HM; O'Riordan MA; Gray WA; Salata RA; Blumer JL
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
    Ruslami R; Nijland HM; Alisjahbana B; Parwati I; van Crevel R; Aarnoutse RE
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2546-51. PubMed ID: 17452486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
    Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
    Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.
    Weiner M; Burman W; Vernon A; Benator D; Peloquin CA; Khan A; Weis S; King B; Shah N; Hodge T;
    Am J Respir Crit Care Med; 2003 May; 167(10):1341-7. PubMed ID: 12531776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.
    Brooks KM; George JM; Pau AK; Rupert A; Mehaffy C; De P; Dobos KM; Kellogg A; McLaughlin M; McManus M; Alfaro RM; Hadigan C; Kovacs JA; Kumar P
    Clin Infect Dis; 2018 Jul; 67(2):193-201. PubMed ID: 29415190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
    Alfarisi O; Alghamdi WA; Al-Shaer MH; Dooley KE; Peloquin CA
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1027-1036. PubMed ID: 28803492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report.
    Tam CM; Chan SL; Lam CW; Leung CC; Kam KM; Morris JS; Mitchison DA
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1726-33. PubMed ID: 9620898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.
    Dooley KE; Luetkemeyer AF; Park JG; Allen R; Cramer Y; Murray S; Sutherland D; Aweeka F; Koletar SL; Marzan F; Bao J; Savic R; Haas DW;
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5245-52. PubMed ID: 24957823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rifapentine: its role in the treatment of tuberculosis.
    Temple ME; Nahata MC
    Ann Pharmacother; 1999 Nov; 33(11):1203-10. PubMed ID: 10573321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of rifapentine in children.
    Blake MJ; Abdel-Rahman SM; Jacobs RF; Lowery NK; Sterling TR; Kearns GL
    Pediatr Infect Dis J; 2006 May; 25(5):405-9. PubMed ID: 16645503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.
    Dooley KE; Bliven-Sizemore EE; Weiner M; Lu Y; Nuermberger EL; Hubbard WC; Fuchs EJ; Melia MT; Burman WJ; Dorman SE
    Clin Pharmacol Ther; 2012 May; 91(5):881-8. PubMed ID: 22472995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.
    Savic RM; Weiner M; MacKenzie WR; Engle M; Whitworth WC; Johnson JL; Nsubuga P; Nahid P; Nguyen NV; Peloquin CA; Dooley KE; Dorman SE;
    Clin Pharmacol Ther; 2017 Aug; 102(2):321-331. PubMed ID: 28124478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.
    Weiner M; Bock N; Peloquin CA; Burman WJ; Khan A; Vernon A; Zhao Z; Weis S; Sterling TR; Hayden K; Goldberg S;
    Am J Respir Crit Care Med; 2004 Jun; 169(11):1191-7. PubMed ID: 14962821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.
    Hibma JE; Radtke KK; Dorman SE; Jindani A; Dooley KE; Weiner M; McIlleron HM; Savic RM
    Am J Respir Crit Care Med; 2020 Sep; 202(6):866-877. PubMed ID: 32412342
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.
    Peloquin CA; Velásquez GE; Lecca L; Calderón RI; Coit J; Milstein M; Osso E; Jimenez J; Tintaya K; Sanchez Garavito E; Vargas Vasquez D; Mitnick CD; Davies G
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.
    Zurlinden TJ; Eppers GJ; Reisfeld B
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4860-8. PubMed ID: 27270284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong.
    Tam CM; Chan SL; Lam CW; Dickinson JM; Mitchison DA
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):411-6. PubMed ID: 9441094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.
    Acosta EP; Kendall MA; Gerber JG; Alston-Smith B; Koletar SL; Zolopa AR; Agarwala S; Child M; Bertz R; Hosey L; Haas DW
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3104-10. PubMed ID: 17576825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rifapentine for the treatment of pulmonary tuberculosis.
    Munsiff SS; Kambili C; Ahuja SD
    Clin Infect Dis; 2006 Dec; 43(11):1468-75. PubMed ID: 17083024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.